To Evaluate the PK, PD, Safety and Drug Tolerance of JW0302 in Healthy Volunteers
NCT ID: NCT05784155
Last Updated: 2024-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
44 participants
INTERVENTIONAL
2023-03-10
2023-06-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To evaluate the safety and drug tolerance after administration of Reference Drug or Test Drug in healthy volunteers under fasting conditions
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the PK, PD, Safety and Drug Tolerance in Healthy Volunteers
NCT05433844
To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105
NCT06754943
Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers
NCT04018170
To Evaluate the Safety and the Pharmacokinetics of NVP-2203
NCT05725252
Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031
NCT01522586
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Test Drug for Period I Reference Drug for Period II
Test Drug(JW0302) or Reference Drug(C2206)
Test Drug: single administration of JW0302 Reference Drug: single administration of C2206
Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration
Group 2
Reference Drug for Period I Test Drug for Period II
Test Drug(JW0302) or Reference Drug(C2206)
Test Drug: single administration of JW0302 Reference Drug: single administration of C2206
Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Test Drug(JW0302) or Reference Drug(C2206)
Test Drug: single administration of JW0302 Reference Drug: single administration of C2206
Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
19 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JW Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
SeungHwan Lee, PI
Role: PRINCIPAL_INVESTIGATOR
Clinical Trial Center, Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Center, Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JW22106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.